《Nature,3月16日,Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-03-17
  • Around the world, I am seeing efforts to support ‘quick-fix’ programmes aimed at developing vaccines and therapeutics against COVID-19. Groups in the United States and China are already planning to test vaccines in healthy human volunteers. Make no mistake, it’s essential that we work as hard and fast as possible to develop drugs and vaccines that are widely available across the world. But it is important not to cut corners.

  • 原文来源:https://www.nature.com/articles/d41586-020-00751-9
相关报告
  • 《3月16日_Nature称COVID-19疫苗在未做足安全评价前不应急于投入使用》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-17
    • 1.时间:2020年3月16日 2.信息来源:Nature 3.事件概要: Nature发表题为“Don’trush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees”的新闻稿,称疫苗在投入使用之前应充分做好安全评价工作,确保疫苗的安全性。 据世卫组织报道,目前COVID-19的致死率为3.4%,远低于埃博拉病毒的致死率,但此次病毒的传播性很强,意味更需要疫苗来控制病毒的传播。有关部分已经投入疫苗的研发,并期望在4月份可以进行人体试验。但部分学者担心,急于开发疫苗而未充分做好临床前评价,会引起不必要的损失。 4.附件: 原文链接:https://www.nature.com/articles/d41586-020-00751-9
  • 《Nature,6月16日,Age-dependent effects in the transmission and control of COVID-19 epidemics》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-06-17
    • Age-dependent effects in the transmission and control of COVID-19 epidemics Nicholas G. Davies, Petra Klepac, Yang Liu, Kiesha Prem, Mark Jit, CMMID COVID-19 working group & Rosalind M. Eggo Nature Medicine (2020) Abstract The COVID-19 pandemic has shown a markedly low proportion of cases among children1,2,3,4. Age disparities in observed cases could be explained by children having lower susceptibility to infection, lower propensity to show clinical symptoms or both. We evaluate these possibilities by fitting an age-structured mathematical model to epidemic data from China, Italy, Japan, Singapore, Canada and South Korea. We estimate that susceptibility to infection in individuals under 20 years of age is approximately half that of adults aged over 20 years, and that clinical symptoms manifest in 21% (95% credible interval: 12–31%) of infections in 10- to 19-year-olds, rising to 69% (57–82%) of infections in people aged over 70 years. Accordingly, we find that interventions aimed at children might have a relatively small impact on reducing SARS-CoV-2 transmission, particularly if the transmissibility of subclinical infections is low. Our age-specific clinical fraction and susceptibility estimates have implications for the expected global burden of COVID-19, as a result of demographic differences across settings. In countries with younger population structures—such as many low-income countries—the expected per capita incidence of clinical cases would be lower than in countries with older population structures, although it is likely that comorbidities in low-income countries will also influence disease severity. Without effective control measures, regions with relatively older populations could see disproportionally more cases of COVID-19, particularly in the later stages of an unmitigated epidemic.